Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries

Journal of Molecular Biology

Volumn 305, Issue 4, 2001, Pages 773-783

  Stoop, A Allart ^a   Eldering, Eric ^a   Dafforn, Timothy R ^b   Read, Randy J ^b   Pannekoek, Hans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

DNA shuffling; PAI 1; Phage display; Protein stability; RCL insertion

Indexed keywords

DNA; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME INHIBITION; HALF LIFE TIME; HUMAN; INHIBITION KINETICS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SURFACE PLASMON RESONANCE;

EID: 0035951303     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.4356     Document Type: Article

References (52)

1. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site
2. Molecular evolution of plasminogen activator inhibitor-1 functional stability
3. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis
4. The biostructural pathology of the serpins: Critical function of sheet opening mechanism
5. Tuning the activity of an enzyme for unusual environments: Sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide
6. Engineering human prolactin to bind to the human growth hormone receptor
7. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
8. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
9. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin
10. Brief report: Complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation
11. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene
12. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
13. Directed evolution of a thermostable esterase
14. Inactive conformation of the serpin alpha(1)-antichymotrypsin indicates two-stage insertion of the reactive loop: Implications for inhibitory function and conformational disease
15. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
16. Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1
17. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A
18. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability
19. Localization of vitronectin binding domain in plasminogen activator inhibitor-1
20. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates
21. Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into beta-sheet A
22. Probing the native strain in alpha1-antitrypsin
23. Regulation of cell adhesion by PAI-1
24. In vitro evolution of thermostable p53 variants
25. Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents
26. Structural basis of latency in plasminogen activator inhibitor-1
27. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
28. Redesigning the substrate specificity of an enzyme by cumulative effects of the mutations of non-active site residues
29. Large increases in general stability for subtilisin BPN' through incremental changes in the free energy of unfolding
30. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate
31. Phage-display technology-finding a needle in a vast molecular haystack
32. Engineering multiple properties of a protein by combinatorial mutagenesis
33. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
34. A structural view of evolutionary divergence
35. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin
36. Rapid evolution of a protein in vitro by DNA shuffling
37. High density mutagenesis by combined DNA shuffling and phage display to assign essential amino acids in protein-protein interactions: Application to study structure-function of Plasminogen Activator Inhibitor 1
38. Functional effects of single amino acid substitutions in the region of Phe113 to Asp138 in the plasminogen activator inhibitor 1 molecule
39. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition
40. Structure of PAI-1 and its function in fibrinolysis: An update
41. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1)
42. Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator
43. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin
44. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins
45. Plasmin and plasminogen activator inhibitor type I promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
46. Additivity of mutational effects in proteins
47. Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin
48. Structural basis for serpin inhibitor activity
49. Optimization of DNA shuffling for high fidelity recombination
50. Molecular evolution by staggered extension process (StEP) in vitro recombination